Literature DB >> 75197

Origin and evolution of benign prostatic enlargement.

J E McNeal.   

Abstract

Important features of the origin and evolution of benign prostatic enlargement (BPH) remain unclarified, partly because of imprecision in previous morphologic observations. Precise, quantitative analysis was applied to BPH development in 63 autopsy prostates. BPH nodules originated selectively from a very small region, near a cylindrical urethral sphincter above the verumontanum, and usually on the outer aspect of that sphincter laterally. They arose in a newly described transition zone, in which the unique mingling of prostatic glands with sphincteric stroma may be implicated in BPH pathogenesis. Nodules originate through eccentric duct budding toward a focus, suggesting local stromal inductive effects. BPH evolved through three processes: early diffuse gland growth, small nodule proliferation, and later nodule enlargement. If these are independent processes, BPH etiology may be multifactorial.

Entities:  

Mesh:

Year:  1978        PMID: 75197

Source DB:  PubMed          Journal:  Invest Urol        ISSN: 0021-0005


  111 in total

Review 1.  Review of current and future approaches to the management of benign prostatic hyperplasia.

Authors:  J C Gingell
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

2.  Partial purification and characterization of a growth factor from human hyperplastic prostatic tissues.

Authors:  A Dignass; A W Holldorf
Journal:  Urol Res       Date:  1992

3.  Towards the prevention and management of prostatic diseases in Nigeria: a framework.

Authors:  Chukwunonso Ecc Ejike
Journal:  Malays J Med Sci       Date:  2011-07

Review 4.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

5.  Can Apparent Diffusion Coefficient Values Assist PI-RADS Version 2 DWI Scoring? A Correlation Study Using the PI-RADSv2 and International Society of Urological Pathology Systems.

Authors:  Sonia Gaur; Stephanie Harmon; Lauren Rosenblum; Matthew D Greer; Sherif Mehralivand; Mehmet Coskun; Maria J Merino; Bradford J Wood; Joanna H Shih; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  AJR Am J Roentgenol       Date:  2018-05-07       Impact factor: 3.959

Review 6.  Personalized medicine for the management of benign prostatic hyperplasia.

Authors:  Seth K Bechis; Alexander G Otsetov; Rongbin Ge; Aria F Olumi
Journal:  J Urol       Date:  2014-02-25       Impact factor: 7.450

Review 7.  Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 8.  Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.

Authors:  M I Wilde; A Fitton; D McTavish
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

9.  Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia.

Authors:  A P Berger; M Deibl; E J Halpern; M Lechleitner; J Bektic; W Horninger; G Fritsche; H Steiner; A Pelzer; G Bartsch; F Frauscher
Journal:  Diabetologia       Date:  2005-03-09       Impact factor: 10.122

10.  The accumulation of versican in the nodules of benign prostatic hyperplasia.

Authors:  Lawrence D True; Sarah Hawley; Thomas H Norwood; Kathleen R Braun; Stephen P Evanko; Christina K Chan; Richard C LeBaron; Thomas N Wight
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.